

✓Breast Medical Oncologist Clinical Trial Leader. University of Maryland, Greenebaum Cancer Center. Tweets= own opinion


2026 will be remembered as a truly transformative year in breast oncology

The evERA study / giredestrant approval is interesting because the @FDA did not approve the drug for the whole study population. The evERA trial accrued for tumors w/w/o ESR1 mutations. The overall result was positive. But study was designed to focus on ESR1 mutated tumors, and there was no/minimal benefit in ESR1 wildtype cohort. So FDA only granted approval into the already-crowded space of 2nd line ET for ESR1 mutated tumors. Here are data from @NEJM Supplemental appendix for the ESR1 wt subset (below).

Okay, this is my favorite oral SERD name. Wilserdly sounds like a proper gentleman.

We have a new FDA-approved oral SERD combo for HR+ mBC! In evERA, led by @elmayermd, giredestrant (vs SoC ET) + everolimus nearly doubled PFS (10 vs 5.5 mo) and ORR (27% vs 14%) in patients with ESR1 mutations. Another important option for our patients! fda.gov/drugs/cancer-approva…

the @FDA has declined to approve ivonescimab in advanced NSCLC because of lack of OS benefit*. Interesting how the 'culture' of different diseases affects norms and standards for regulatory approval. The landscape of advanced breast cancer treatment would look very different and have different kinetics if OS was required for approval. *this instance may also be affected by the fully ex-US nature of the particular trial smmttx.com/news/press-releas…

Join us for a webinar on Navigating Changes in Body and Intimacy While Living with #MetastaticBreastCancer on 🗓️ December 9, 2026 | 11 a.m. – 12 p.m. ET. Hear from experts Sharon Bober, PhD (@DrSharonBober), and Teresa Neira, PhD, LICSW, about common concerns related to body image and sexual health, and ways to navigate these changes with yourself and a partner. The webinar will include a Q&A session with an opportunity to ask questions anonymously. This event is part of the 2026–2027 EMBRACE Metastatic #BreastCancer Forum, a series of free virtual educational programs for patients, families, and loved ones. Register: dana-farber.org/cancer-care/…

This has been one of the best days of my life


I am delighted to share that the results of the INTerpath-001 trial have been published in the @NEJM. It was a privilege to lead this study as first author and chair of the steering committee, together with medical oncology colleagues from around the world and at @MelanomaAus. The trial tested a personalised therapeutic cancer vaccine, as distinct from a preventative vaccine, combined with pembrolizumab. It was given to people with melanoma who had already had surgery but were at high risk of the cancer coming back. The therapy is made for each person, based on the changes found in their own tumour. Adding the personalised therapy to pembrolizumab reduced the risk of the cancer returning or of death by 58% compared with pembrolizumab alone, from 6 months after the start of therapy. This result rests on science, and science rests on facts. It stands on more than a century of incremental discovery and innovation, with each generation building on the last. What I love most is the spirit of exploration: we never assume we have it right, and we keep learning and refining. Go #science! None of this would be possible without the patients and families who took part, and the teams at every site who worked so generously together across many countries. Thank you to everyone involved. This is what global collaboration looks like, and I am so grateful to be part of it. Read the full paper > bit.ly/48IDpk8 #intismeran #CancerVaccine @Sydney_Uni @syd_health @Science_Academy @AAHMS_health @FulbrightAUS @NthSydHealth @ausoftheyear

@DrHBurstein belongs in D.C. as well as at @DFCI_BreastOnc! You always do an amazing job reviewing new data and putting it in the context of real-world practice.

Fantastic evening discussing updates on the management of breast cancer in Rochester New York! An OncLive event. @WilmotCancer

Congratulations @adawaksmd on being named Vice Chair for Correlative Science at @ALLIANCE_org Could not have appointed a better person

Doctors are about to take a 20% pay cut for doing a procedure the same day they see the patient. They get penalized for helping the patient on the spot.

Many young women with breast and gyn cancers go into menopause overnight from treatment: ovarian suppression, tamoxifen or an AI, oophorectomy, pelvic radiation, chemotherapy. Hot flashes, no sleep, painful sex. Some stop the pill that protects them from recurrence. What we can offer: -- Hormone therapy: not a blanket no. It can be reasonable for some survivors; but after HR+ breast cancer it is generally avoided. -- #Elinzanetant (Lynkuet): nonhormonal NK1/NK3 blocker, FDA approved for menopausal hot flashes. 120 mg at bedtime, LFTs at baseline and 3 months, check CYP3A4 interactions. Reduced hot flashes on endocrine therapy in OASIS-4; in the US that use is still under FDA review. -- Venlafaxine or gabapentin: older, effective options. -- Vaginal dryness: moisturizers and lubricants first. Ask about it every visit. Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer | New England Journal of Medicine nejm.org/doi/10.1056/NEJMoa2…

It's annual paycut season for doctors, brought to us by @CMSGov… And, drumroll…it's a cut. Again. -2.31% for most of the house of medicine in 2027 on the RVU conversion factor (to $32.63/RVU). Adjusted for inflation, that's: A one-year 4.7% decrease, A 10-year cut of 32.6%, A 20-year cut of 46%. Yikes. Thanks, @RobertKennedyJr. 😬😬😬